Yurike Laurensia

Singapore, Singapore

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

A genomic-augmented multivariate prognostic model for the survival of natural-killer/T-cell lymphoma patients from an international cohort.

A genomic-augmented multivariate prognostic model for the survival of natural-killer/T-cell lymphoma patients from an international cohort.

Journal: American journal of hematology
Published: December 13, 2021

Correction to: Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma.

Correction to: Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma.

Journal: Leukemia
Published: March 09, 2021

No association between ECSIT germline mutations and hemophagocytic lymphohistiocytosis in natural killer/T-cell lymphoma.

No association between ECSIT germline mutations and hemophagocytic lymphohistiocytosis in natural killer/T-cell lymphoma.

Journal: Haematologica
Published: August 12, 2020

Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study.

Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study.

Journal: Blood
Published: May 28, 2020

Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma.

Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma.

Journal: Leukemia
Published: May 21, 2020

Whole-genome sequencing reveals potent therapeutic strategy for monomorphic epitheliotropic intestinal T-cell lymphoma.

Whole-genome sequencing reveals potent therapeutic strategy for monomorphic epitheliotropic intestinal T-cell lymphoma.

Journal: Blood advances
Published: March 02, 2020

Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphoma.

Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphoma.

Journal: Blood cancer journal
Published: November 05, 2019

Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations.

Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations.

Journal: The Lancet. Oncology
Published: September 11, 2019

Evaluation of the PIK3 pathway in peripheral T-cell lymphoma and NK/T-cell lymphoma.

Evaluation of the PIK3 pathway in peripheral T-cell lymphoma and NK/T-cell lymphoma.

Journal: British journal of haematology
Published: September 02, 2019

A clinicohaematological prognostic model for nasal-type natural killer/T-cell lymphoma: A multicenter study.

A clinicohaematological prognostic model for nasal-type natural killer/T-cell lymphoma: A multicenter study.

Journal: Scientific reports
Published: May 13, 2019

Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma.

Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma.

Journal: Leukemia
Published: October 01, 2018

Whole exome sequencing identifies recessive germline mutations in FAM160A1 in familial NK/T cell lymphoma.

Whole exome sequencing identifies recessive germline mutations in FAM160A1 in familial NK/T cell lymphoma.

Journal: Blood cancer journal
Published: June 26, 2018
Showing 1-12 of 16

Last Updated: 09/26/2026